First Time Loading...

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 45.27 USD 0.67%
Updated: May 21, 2024

Halozyme Therapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Halozyme Therapeutics Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Halozyme Therapeutics Inc
NASDAQ:HALO
Income from Continuing Operations
$318.8m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$6B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$4B
CAGR 3-Years
13%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Halozyme Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
318.8m USD

Based on the financial report for Mar 31, 2024, Halozyme Therapeutics Inc's Income from Continuing Operations amounts to 318.8m USD.

What is Halozyme Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
25%

Over the last year, the Income from Continuing Operations growth was 76%. The average annual Income from Continuing Operations growth rates for Halozyme Therapeutics Inc have been 25% over the past three years .